Aimmune Therapeutics Announces Closing of $98 Million Investment by Nestlé Health Science
November 28 2018 - 4:05PM
Business Wire
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical
company developing treatments for potentially life-threatening food
allergies, today announced the closing of the $98 million equity
investment by Nestlé Health Science. Nestlé Health Science
purchased 3,237,529 newly issued shares of Aimmune’s common stock
at $30.27 per share on November 28, 2018, in a private placement
transaction. The sale of shares was made pursuant to the terms of
the Securities Purchase Agreement entered into on November 11,
2018, by Aimmune and Nestlé Health Science, as previously reported
by Aimmune.
Additional details regarding the equity investment and strategic
collaboration agreement can be found in Aimmune’s Form 8-K filed
with the Securities and Exchange Commission on November 13,
2018.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a biopharmaceutical company
developing treatments for life-threatening food allergies. The
company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™)
approach is intended to provide meaningful levels of protection
against allergic reactions resulting from accidental exposure to
food allergens by desensitizing patients with defined, precise
amounts of key allergens. Aimmune’s first investigational biologic
product using CODIT™, AR101 for the treatment of peanut allergy,
has received the FDA’s Breakthrough Therapy Designation for the
desensitization of peanut-allergic patients 4–17 years of age.
Aimmune plans to submit regulatory filings for marketing approval
of AR101 in the United States and Europe based on data from the
pivotal Phase 3 PALISADE clinical trial of AR101, which in
4–17-year-old subjects met its primary and key secondary endpoints,
and additional ongoing and completed AR101 clinical trials. For
more information, please see www.aimmune.com.
This press release concerns a product that is under clinical
investigation and that has not yet been approved for marketing by
the U.S. Food and Drug Administration (FDA) or the European
Medicines Agency (EMA). It is currently limited to investigational
use, and no representation is made as to its safety or
effectiveness for the purposes for which it is being
investigated.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181128005724/en/
InvestorsLaura Hansen, Ph.D.(650)
396-3814lhansen@aimmune.com
MediaAlison Marquiss(650) 376-5583amarquiss@aimmune.com
Aimmune Therapeutics (NASDAQ:AIMT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aimmune Therapeutics (NASDAQ:AIMT)
Historical Stock Chart
From Sep 2023 to Sep 2024